Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ensemble internally developed novel synthetic macrocycle drugs (Ensemblins) for undruggable targets but did not advance any in-house drugs to late clinical stage. The IL-17 antagonist program was out-licensed to Novartis; other partnerships (Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Alexion, Genentech) focused on early discovery using macrocycle libraries. No programs reached commercialization under Ensemble's control
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ensemble Group.